Prognostic value of serum microRNA-122 in hepatocellular carcinoma is dependent on coexisting clinical and laboratory factors

Figure 4 Survival analysis of subgroups of patients depending on serum microRNA-122 level. A: Survival analysis in relation to serum miR-122 in all patients [divided into two groups: < 25^th percentile (n = 22), ≥ 25^th percentile (n = 69)]; B: Survival analysis in relation to serum miR-122 in patients with Child-Pugh class B or C [divided into two groups: < 25^th percentile (n = 7), ≥ 25% percentile (n = 23)]; C: Survival analysis in relation to serum miR-122 in patients with Barcelona clinic liver cancer stage B/C/D [divided into two groups: < 25^th percentile (n = 18), ≥ 25^th percentile (n = 57)]; D: Survival analysis in relation to serum miR-122 in patients with normal alpha-fetoprotein (AFP) (AFP < 7 ng/mL) [divided into two groups: < 25^th percentile (n = 8), ≥ 25^th percentile (n = 25)]. Nonparametric log-rank test was used for statistical analysis. P < 0.05 miR-122 < 25^th percentile vs miR-122 ≥ 25^th percentile. BCLC: Barcelona clinic liver cancer; AFP: Alpha-fetoprotein.